On August 31, 2021 Ixaka Ltd, an integrated cell and gene therapy company, reported that Dr Cecile Bauche, Chief Scientific Officer, will present its in vivo gene delivery platform and the key bioproduction challenges associated with advancing an in vivo CAR-T therapy into the clinic at the 6th CAR TCR Summit on Tuesday, 31 August, 2021 at 2.30pm ET / 11.30am PT (Press release, Ixaka, AUG 31, 2021, View Source [SID1234587059]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ixaka’s nanoparticle-based in vivo gene delivery technology is a highly promising platform for the development of in vivo CAR-T therapies. Dr Bauche will present on the different components of the platform and then the lessons learned from progressing Ixaka’s lead program for CD19 haematological malignancies (CELTIC) towards first-in-man clinical studies. The presentation will discuss how lentiviral vector design and bioproduction are key for in vivo gene delivery platforms and outline the anticipated regulatory pathway and associated quality controls. Dr Bauche will also chair a discussion on the development of relevant animal models for developing cell therapies at 4.00pm ET / 1.30pm PT.

"Our nanoparticle-based in vivo gene delivery technology is ideally positioned to deliver on the promise of in vivo CAR-T therapies to transform cancer treatment without the need for costly dedicated manufacturing sites for T-cell modification. The CAR TCR Summit is now one of the key events in the industry calendar, with leaders from the entire field represented. We are therefore delighted to share our latest insights from the development of an in vivo anti-CD19 CAR T-cell therapy based on a chemically encapsulated lentiviral vector," commented Dr. Cecile Bauche, Vice President & Chief Scientific Officer, at Ixaka.

A further five posters will also be presented at the conference covering a range of applications of the nanoparticle-based in vivo gene delivery platform. In addition to further detail on the CELTIC program, progress with proprietary anti-CD3 aptamers, selected by Ixaka as targeting agents, will be made available.